Ç°ÑÔ
ÈËÀàȱѪÐÔÐÄÔಡ°üÀ¨ÐĽÊÍ´ºÍÐļ¡¹£ËÀ£¬²¢Çһᱬ·¢Ðļ¡ÏËά»¯ºÍÐÄË¥¡£µ¼ÖÂÐļ¡È±ÑªµÄ×î³£¼ûÔµ¹ÊÔÓÉÊÇÖ¸¹Ú×´¶¯ÂöÖàÑùÓ²»¯»ù´¡ÉÏ£¬¹Ú×´¶¯Âö¾·ÂλòÛÕ±Õµ¼ÖÂÐļ¡È±ÑªÈ±Ñõ»ò»µËÀ£¬¼´¹Ú×´¶¯ÂöÓ²»¯ÐÔÐÄÔಡ(coronary atherosclerotic heart disease)£¬¼ò³Æ¹ÚÐIJ¡¡£Ëü²»µ«ÔÚÅ¹ú¼Ò³£¼û£¬ÔÚÎÒ¹úÒ²³ÊÖðÄêÔöÌíÇ÷ÊÆ£¬½üÄêÀ´³ÉΪÎÒ¹úéæÃüÂÊÇ°Á½Î»µÄ¼²²¡Ö®Ò»¡£Õë¶Ô¹ÚÐIJ¡µÄÒ©ÎïÆÀ¼Û£¬Ò»Ö±Ã»ÓкÜÀû±ãÊÊÓõĶ¯ÎïÄ£×Ó£¬Ö÷ÒªÓÉÓÚ±£´æһЩǷºÃ½â¾öµÄÄÑÌâ¡£Ê×ÏÈ£¬ÊÖÊõÓÕ·¢ÀàµÄÄ£×Ó£¬ÊÖÒÕÄѶȴó£¬ÌØÊâÔÚС¶¯ÎïÉϲÙ×÷µÄÒ»ÖÂÐÔÇ·ºÃ¿ØÖÆ£¬¶ø´ó¶¯Îï¹ØÓÚÒ©ÎïÆÀ¼Û²»ÊǺܱ㵱£¬Ð¡¶¯Îïͬʱ»¹±£´æÐĵç¼à¿ØµÈרҵÒÇÆ÷µÄÏÞÖÆ¡£ÁíÍ⣬ÈËÀàÐÄѪ¹ÜϵͳÌصãÒÔ¼°ÔÚijЩÇéÐÎÒòËØ£¨ÈçÓ¦¼¤£©Ï·¢²¡µÄÌص㣬ÔÚ³£ÓõÄС¶¯ÎïÄ£×ÓÉ϶¼ºÜÄÑÄ£Ä⣬ÏÖÓÐÄ£×ÓºÍÈËÀ༲²¡µÄÏÖÕæÏàÐβî±ðºÜ´ó¡£¾¡¿ÉÄÜÄ£ÄâÈËÀ༲²¡µÄ²¡ÒòºÍ²¡Àí»úÖÆ£¬ÎªÑ°ÕÒȱѪÐÔÐÄÔಡµÄ·ÀÖβ½·¥ÌṩºÜºÃµÄÑо¿Æ½Ì¨£¬ÊÇÕâÀàÄ£×ÓÑо¿µÄÉú³¤Æ«Ïò¡£
ÂýÐÔÐļ¡È±Ñª¶¯ÎïÄ£×ÓÊǹÚ×´¶¯Âö½¥½øÐÔÛÕ±Õ»òÏÁÕ£¬Öð½¥µ¼ÖÂÐļ¡È±Ñª£¬²¢ÓÉ´ËÐγÉȱѪÐÔÐļ¡²¡±ä£¬Ô½·¢ÇкÏÁÙ´²²¡ÀíÐÄÀíÀú³Ì£¬ÏàÒ˶à´Î¸øÒ©ºÍ³¤Ê±¼ä¾ÙÐÐÐĹ¦Ð§ÊӲ졣
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÐÍÖí¡¢È®
¡¾ÔìÄ£»úÖÆ¡¿£º
AmeroidËõÕ»·ÊÇÒ»ÖÖÄÚ¾¶Îª2.0~2.5mmµÄË«²ã»·£¬Íâ²ãΪ½ðÊô¡¢ËÜÁÏ»òÆäËûÖÊÁÏ£¬ÄÚ²ãΪÀÒÂÑ°×£¬ÎüË®ºó»áÅòÕÍ¡£ÓÉÓÚÍâ²ã²»¿É±äÐΣ¬ÀÒÂÑ°×ÅòÕͺóÖ»ÄÜÏòÄÚ¼·Ñ¹£¬Öð½¥ËõÕѪ¹ÜÄÚ¾¶²¢×îÖÕ±ÕÈû£¬Ôì³ÉÂýÐÔÐļ¡È±Ñª¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
Ô¼¿ËÏÄÖí£ºÐÔ±ð²»ÏÞ£¬ÓÃÂÈ°·Íª¼¡×¢Âé×í£¬Ó÷úÍéά´ýÂé×í£¬ÓÒÍÈÍ䲿Çпª£¬4F¶¯Âöµ¼¹Ü²å¹Ü£¬ÒÔ±ãÈ¡ÑùºÍѪѹ¼ì²â£¬µÚ4Àß¼ä϶×ó²àÐпªÐØÊõ£¬ÇпªÐÄ°ü£¬ÔÚ×ó¹Ú×´¶¯ÂöÅÌÐýÖ§ÉÏ(LCX)°²ÅÅÄÚ¾¶2.5mmµÄAmeroidËõ¶Ì»·£¬6ºÅ¾Û±ûÏ©·ÄÖ¯ÏËάÏß·ìºÏÐÄ°üºÍÐØÇ»£¬Æ¾Ö¤ÐèÒª¼¡×¢¿¹ÉúËغÍֹʹҩ¡£
°ÍÂíСÐÍÖí£ºÄêËê9¸öÔ£¬Ê×Ïȼ¡ÄÚ×¢ÉäÂÈ°·Íª9mg/kg¡¢ÈüÀàÂ(xylazine) 1.5mg/kg¡¢°¢ÍÐÆ·0.05mg/kg½øÈë»ù´¡Âé×í£¬¾¿ÚÇ»ÐÐÆø¹Ü²å¹Ü£¬²å¹ÜÀֳɺó½ÓºôÎü»ú¾ÙÐи¨ÖúºôÎü£¬³±ÓîÁ¿Îª12~15ml£¬ºôÎüƵÂÊΪ15~18´Î£¯min£¬ÎüÈë15~20g/LÒì·úÍéά³ÖÂé×í¡£µÚ4Àß¼ä϶×ó²àÐпªÐØÊõ£¬×¢Öر£»¤×ó·Î£¬ÇпªÐÄ°ü£¬Ì»Â¶¹Ú×´¶¯ÂöµÄ×óÅÌÐýÖ§£¬ÔÚ×óÅÌÐýÖ§¹Ú×´¶¯ÂöÉÏ°²ÅÅÄÚ¾¶2.25~2.50mmµÄAmeroidËõ¶Ì»·ËõÕLCX£¬¹Ø±ÕÐÄ°ü£¬Öð²ã¹ØÐØ£¬Êõºó×¢É俹ÉúËØÔ¤·ÀѬȾ¡£
È®£ºÓ¦ÓóÉÄêÔÓÖÖÈ®4ͨÀýÂé×í£¬Æø¹Ü²å¹Ü£¬ºôÎü»úͨÆø£¬ÐпªÐØÊõ£¬ÊèÉ¢LCX½ü¶Ë£¬°²ÅÅÄÚ¾¶Îª2.77mmµÄAmeor¼ÇËõ¶Ì»·£¬Ô¼3ÖܺóÄ£×ÓÖƱ¸Àֳɡ£
¡¾ÔìÄ£Ìص㡿£º
ÔÚÅÌÐýÖ§½üÐĶ˰²ÅÅAmeroidËõÕÆ÷·¨±¬·¢Ä£×ÓµÄʱ¼ä¶Ì£¬ÊÔÑéЧ¹û¿É¿¿¡£Ð¡ÐÍÖíµÄÐÄÔà³ýÁ鳤ÀදÎïÒÔÍ⣬ÓëÈËÀà×îΪ¿¿½ü¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
Ó¦ÓÃAmeroidËõ¶Ì»··¨Æ½¾ù6ÖܺóÄ£×Ó¶¯Îï·ºÆð½¥½øÐÔ×óÐÄÊÒ·Ê´ó£¬ËùÓлò¾Ö²¿×óÐÄÊÒËõ¶Ì¹¦Ð§ÕÏ°£¬Ô¼Äª1/3¶¯ÎïÔì³É¾Ö²¿ÂýÐÔÐļ¡È±ÑªË𺦣¬Ðļ¡»µËÀºÜÉÙ·ºÆð£¬ÇкÏÂýÐÔÐļ¡È±Ñª²¡ÀíÌص㡣ÏÖÔÚ£¬ÔÚÂýÐÔ¹Ú×´¶¯ÂöÏÁÕµ¼ÖÂÐļ¡È±ÑªºÍ²à֧ѻ·µÄÑо¿Öдó¶à½ÓÄÉAmeroidËõ¶Ì»··¨¡£
²Î¿¼ÎÄÏ×£º
1.ÕÅ¿¡Ò壬ÍõÕýÖÒ£¬´÷ºìÑÞ£¬µÈ£®´óÊóÐļ¡¹£ËÀÄ£×ÓÖÆ×÷ÒªÁì̽ÌÖ£®Çൺ´óѧҽѧԺѧ±¨£¬2013,49(2):121-123
2.¹ùˆÅ£¬ºÂ࣬Àî·å½Ü£¬µÈ£®BeagleÈ®ÓëÔÓÖÖÈ®¼±ÐÔÐļ¡¹£ËÀÄ£×ӵĽÏÁ¿£®ÖйúÖÐÒ©ÔÓÖ¾£¬2013,28 (12):2001-2004
3.Cozen AE, Moriwaki H, Kremen M, el al. Macrophage targeted overexpression of urokinase causes acceleratedatherosclerosis,coronary artery occlusions, and premature death. Circulation, 2004,09 (17):2129-2135
4.Cullen P,Baella R,Bellosla S,el al. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vase Biol, 2003, 23 (4):535-542
5.Fernandez-Hernando C,Ackah E, Yu J,el al. Loss of Aktl leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab,2007, 6 (6):446-457
6.Kuhlencordt PJ, Gyurko R, Han F, et al. Accelerated atherosclerosis,aortic aneurysm formation, and ischernic heart disease in apolipoprotein E/endolhelial nitric oxide synthase double-knockout mice. Circulation, 2001, 104 (4):448-454
7.Nakata S, Tsutsui M, Shimokawa H,et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation, 2008, 117 (17):2211- 2223
8.Shiomi M,Ito T. The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of devel opment: a tribute to the late Dr. Yoshio Watanabe., Atherosclerosis, 2009, 207 (1):1-7
9.Trigalli B, Rayburn H, Viiials M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci U S A, 1999,96 (16):9322-9327
10.Zhang S,Picard MH, Vasile E,et al. Diel-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction,and premature death in scavenger receptor class B lype 1-deficient,hypomorphic apolipoprotein ER61 mice. Circulation, 2005, 111(25): 3457-3464